S&P 500   3,319.18 (+1.16%)
DOW   27,323.41 (+0.65%)
QQQ   271.96 (+1.66%)
AAPL   111.56 (+1.34%)
MSFT   207.05 (+2.23%)
FB   254.53 (+2.57%)
GOOGL   1,458.41 (+1.98%)
AMZN   3,114.23 (+5.19%)
NVDA   502.89 (+0.44%)
TSLA   423.25 (-5.82%)
BABA   274.37 (+0.20%)
CGC   16.08 (+2.16%)
GE   6.25 (-1.57%)
MU   49.58 (+0.87%)
AMD   77.33 (-0.78%)
T   28.52 (-0.38%)
F   6.80 (-1.02%)
ACB   7.46 (+18.04%)
GILD   63.53 (-1.06%)
NFLX   490.48 (+0.64%)
DIS   127.14 (+1.38%)
BAC   23.86 (-2.49%)
BA   156.63 (+0.18%)
S&P 500   3,319.18 (+1.16%)
DOW   27,323.41 (+0.65%)
QQQ   271.96 (+1.66%)
AAPL   111.56 (+1.34%)
MSFT   207.05 (+2.23%)
FB   254.53 (+2.57%)
GOOGL   1,458.41 (+1.98%)
AMZN   3,114.23 (+5.19%)
NVDA   502.89 (+0.44%)
TSLA   423.25 (-5.82%)
BABA   274.37 (+0.20%)
CGC   16.08 (+2.16%)
GE   6.25 (-1.57%)
MU   49.58 (+0.87%)
AMD   77.33 (-0.78%)
T   28.52 (-0.38%)
F   6.80 (-1.02%)
ACB   7.46 (+18.04%)
GILD   63.53 (-1.06%)
NFLX   490.48 (+0.64%)
DIS   127.14 (+1.38%)
BAC   23.86 (-2.49%)
BA   156.63 (+0.18%)
S&P 500   3,319.18 (+1.16%)
DOW   27,323.41 (+0.65%)
QQQ   271.96 (+1.66%)
AAPL   111.56 (+1.34%)
MSFT   207.05 (+2.23%)
FB   254.53 (+2.57%)
GOOGL   1,458.41 (+1.98%)
AMZN   3,114.23 (+5.19%)
NVDA   502.89 (+0.44%)
TSLA   423.25 (-5.82%)
BABA   274.37 (+0.20%)
CGC   16.08 (+2.16%)
GE   6.25 (-1.57%)
MU   49.58 (+0.87%)
AMD   77.33 (-0.78%)
T   28.52 (-0.38%)
F   6.80 (-1.02%)
ACB   7.46 (+18.04%)
GILD   63.53 (-1.06%)
NFLX   490.48 (+0.64%)
DIS   127.14 (+1.38%)
BAC   23.86 (-2.49%)
BA   156.63 (+0.18%)
S&P 500   3,319.18 (+1.16%)
DOW   27,323.41 (+0.65%)
QQQ   271.96 (+1.66%)
AAPL   111.56 (+1.34%)
MSFT   207.05 (+2.23%)
FB   254.53 (+2.57%)
GOOGL   1,458.41 (+1.98%)
AMZN   3,114.23 (+5.19%)
NVDA   502.89 (+0.44%)
TSLA   423.25 (-5.82%)
BABA   274.37 (+0.20%)
CGC   16.08 (+2.16%)
GE   6.25 (-1.57%)
MU   49.58 (+0.87%)
AMD   77.33 (-0.78%)
T   28.52 (-0.38%)
F   6.80 (-1.02%)
ACB   7.46 (+18.04%)
GILD   63.53 (-1.06%)
NFLX   490.48 (+0.64%)
DIS   127.14 (+1.38%)
BAC   23.86 (-2.49%)
BA   156.63 (+0.18%)
Log in
NASDAQ:LPDX

LipoScience Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
LipoScience, Inc. is a vitro diagnostic company. The Company's diagnostic test, the nuclear magnetic resonance (NMR) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's Vantera system is the Company's automated clinical analyzer. As of January 25, 2013, over eight million NMR LipoProfile tests were ordered. The Vantera system is its automated clinical analyzer. In August 2012, the Company received Food and Drug Administration (FDA) clearance to market the Vantera system commercially to laboratories.
Read More
LipoScience logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:LPDX
CUSIP53630M10
WebN/A
Phone+1-919-2121999

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive LPDX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











LipoScience (NASDAQ:LPDX) Frequently Asked Questions

How were LipoScience's earnings last quarter?

LipoScience Inc (NASDAQ:LPDX) posted its earnings results on Wednesday, November, 12th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.02. The biotechnology company earned $8.56 million during the quarter, compared to analysts' expectations of $8.80 million. During the same period in the prior year, the business posted ($0.31) EPS.
View LipoScience's earnings history
.

Who are some of LipoScience's key competitors?

What other stocks do shareholders of LipoScience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LipoScience investors own include Altaba (AABA), Global Sources Ltd. (Bermuda) (GSOL), SolarCity (SCTY), Alcoa (AA), Agios Pharmaceuticals (AGIO), AerCap (AER), American Electric Power (AEP), Aegerion Pharmaceuticals (AEGR), AEGON (AEG) and Acorda Therapeutics (ACOR).

What is LipoScience's stock symbol?

LipoScience trades on the NASDAQ under the ticker symbol "LPDX."

How can I contact LipoScience?

LipoScience's mailing address is 2500 Sumner Blvd, RALEIGH, NC 27616-3235, United States. The biotechnology company can be reached via phone at +1-919-2121999.

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.